A recent interview was conducted with Wayne, here is the link...

A recent interview was conducted with Wayne, here is the link and some highlights:

Highlights

* Steps taken lastyear with the sale to Lemaitre have placed Admedus in a better position, the company

otherwise would be paying reps to stay home.

* Action taken in January to stockpile chemicals needed to continue Adapt production without interruption.

* Staggard shifts are in place to continue production, most office staff are working from home.

* SAVR operation crowned with Success, excellent numbers with opening orfice area at 2.9 where usualy the norm is 2.0 - 2.2

* Peak Gradiant isin excellent shape. all normal

* Valve isperforming as good as it performed ni the bench

* Advisory board was very pleased with the result which places Admedus in a great position when it comes to durability.

* New Member to the Advisory board Dr. J. Popma from Harvard.

https://findadoc.bidmc.org/details/1219/jeffrey-popma-cardiovascular_disease-interventional_cardiology-boston

https://www.youtube.com/watch?v=FCu18qVC_8A

* Single piece 3D Valve Design is performing exceptionally well compared to other designs.

* Same Valve used inSavr and TAVR which gives great insights to how the Valve willfunction as a TAVR valve.

* Animal TAVR testing in Q3, depends if labs are still functional....

* 2 Year low risk TAVR Trials, existing valves are still not durable enough, showing wear after two years, which shows durability is king.